Clinical Trial Update: Elitek (Rasburicase) Immuno-Monitoring Study

View source ↗

Summary

This clinical trial update reports that the immuno-monitoring study of Elitek (rasburicase) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tumor Lysis Syndrome

Drugs mentioned

• ELITEK (rasburicase)

Snippet

Sponsor: Sanofi | Conditions: Tumor Lysis Syndrome | Status: TERMINATED